Advertisement Amgen reports increase in Q4 adjusted net income - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Amgen reports increase in Q4 adjusted net income

Amgen has reported adjusted net income, excluding stock option expense and certain other expenses, of $1.12 billion in the fourth quarter of 2008, an increase of 3% compared to $1.08 billion posted in the same period of 2007.

Adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, was $1.06 for the fourth quarter of 2008, an increase of 6% compared to $1 for the fourth quarter of 2007.

Full-year 2008 adjusted EPS, excluding stock option expense and certain other expenses, were $4.55 versus $4.29 in 2007, a 6% increase. Full-year 2008 adjusted net income, excluding stock option expense and certain other expenses, was $4.88 billion versus $4.80 billion in 2007, a 2% increase.

Total revenue of $3.75 billion in the fourth quarter of 2008 was essentially flat compared to $3.74 billion in the fourth quarter of 2007. For the full year 2008, total revenue increased 2% to $15 billion from $14.77 billion in 2007, the company said.

Kevin Sharer, chairman and CEO of Amgen, said: “I am proud of Amgen’s performance in 2008 and excited about our prospects in 2009 and beyond. While Amgen faces a range of challenges in today’s environment, I am confident we are ready.”